Clinical trial · Interventional
PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
PET-MRI: Evaluation, Optimization and Clinical Implementation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized pilot clinical trial studies how well positron emission tomography (PET)-magnetic resonance imaging (MRI) works compared to standard-of-care PET-computed tomography (CT) in diagnosing patients with cancer, cardiac diseases, or neurologic diseases. PET-MRI combines two imaging methods that can be used to evaluate disease. PET-MRI is similar to standard-of-care PET-CT, but exposes the patient to less radiation. It is not yet known whether PET-MRI produces better image quality than PET-CT in diagnosing patients with cancer, cardiac disease, or neurologic disease.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiac Disease | — | UNRESOLVED | — |
| Dementia | — | UNRESOLVED | — |
| FDG Avid Cancers | — | UNRESOLVED | — |
| Fever of Unknown Origin | — | UNRESOLVED | — |
| Inflammatory Disease | — | UNRESOLVED | — |
| Osteomyelitis | — | UNRESOLVED | — |
| Vasculitis | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| computed tomography | Device | — | UNRESOLVED |
| magnetic resonance imaging | Device | — | UNRESOLVED |
| positron emission tomography | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PET-CT and PET-MRI
- description
- Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes.
- interventionNames
- Device: positron emission tomography
- Device: computed tomography
- Device: magnetic resonance imaging
Primary outcomes (5)
- measure
- Overall Image Quality Scores
- timeFrame
- Day 1
- description
- Overall image quality scores obtained from the two imaging modalities will be compared with the hypothesis that hybrid PET-MRI images is as good as PET-CT images or superior (not inferior) to the PET-CT images. Evaluation of overall image quality will be assessed using the following criteria: 1=excellent, 2=good, 3=acceptable, 4=poor, 5=not acceptable. A Wilcoxon (Mann-Whitney) rank-sum test with a 0.100 significance level will be used.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinically indicated PET/PET-CT (with or without clinically indicated diagnostic MRI) * Presenting with one of the four conditions specified below * Fludeoxyglucose F 18 (FDG) avid cancers * Cardiac disease (cardiac viability assessment) * Neurologic disorders (dementia) * Inflammatory disease (for example fever of unknown origin, vasculitis, osteomyelitis) Exclusion Criteria: * Pregnancy and lactation * Contraindications to undergo MRI * Cardiac pacemaker and metal devices (as specified in a separate MRI Informed consent) * Claustrophobia or inability to tolerate MRI examination (lay still for approximately 1 hour and hold breath intermittently) * Previously known allergies against MRI contrast agents (exclusion criterion only for contrast enhanced MRI) * Renal insufficiency: glomerular filtration rate (GFR) \< 40ml/min/1.73m\^2 and following European Society of Urogenital Radiology (ESUR) guidelines (exclusion criterion only for contrast enhanced MRI) * Individuals who are not willing or capable of giving informed consent or assent (with legal guardian consent)
References
Publications (0)
Data not yet available